Still unresolved
sport's first pro cycling ipamorelin finding dropped in august — the case is still active in october 2026
On August 21, 2026, the International Testing Agency announced that S'annara Grove, a South African rider competing for the Smurfit Westrock team, had been provisionally suspended mid-race at the Tour of Britain Women. Her out-of-competition sample from July 28 — collected during the Glasgow Commonwealth Games — returned an adverse analytical finding for ipamorelin. She did not start stage three of the Tour. [Escape Collective covered the suspension on August 21](https://escapecollective.com/sannara-grove-leaves-tour-of-britain-due-to-synthetic-peptide-positive-test/), noting she was reported as the first professional-level cyclist to test positive for the compound. As of October 2026, the ITA has issued no further public statement on the case. Under the World Anti-Doping Code, an adverse analytical finding initiates a process — it does not automatically establish a violation — and Grove is provisionally suspended while that process continues. The Road World Championships in Montreal were held in late September; her eligibility during that window was an open question the case file controls. The substance at the center of it all is ipamorelin, a synthetic GH secretagogue banned at all times under the 2026 WADA Prohibited List in category S2 — peptide hormones, growth factors, related substances and mimetics. It has no FDA-approved indication. The company that developed it, Novo Nordisk, discontinued it after clinical trials did not establish efficacy. That part of the story rarely travels as far as the compound itself.
The molecule
ipamorelin triggers GH pulses through the ghrelin receptor — and the selectivity is the entire pitch
Ipamorelin is a synthetic five-amino-acid peptide that acts as a selective ghrelin receptor agonist — a growth hormone secretagogue, or GHS. When it binds the growth hormone secretagogue receptor (GHSR) in the pituitary, it produces a dose-dependent pulse of growth hormone release. The case for selectivity is where most of the positive framing lives: ipamorelin does not strongly engage ACTH or cortisol pathways the way hexarelin does, and it does not carry the appetite-stimulating signal strongly associated with GHRP-6. That narrower pharmacological footprint made it attractive in the compounding window, positioned as the clean, tolerable GH-axis peptide for optimization stacks. The GH pulse effect is real in the studied contexts. Whether that pulse produces the downstream benefits claimed for it — faster soft-tissue recovery, preserved lean mass during caloric restriction, improved sleep architecture — is what the clinical record has not established. [PubMed's ipamorelin literature](https://pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin) is concentrated in receptor characterization, animal pharmacology, and the narrow Novo Nordisk clinical program. The trail gets thin quickly once you leave the lab.
The stack culture
clinics and forums built the cleaner-GH-peptide narrative — the grove case reveals where it travels
The pitch built around ipamorelin is comparative by design: it is framed as the selective alternative to GHRP-6, the better-tolerated partner for CJC-1295 stacks, the GH secretagogue with more favorable sleep effects and no appetite side effect to manage. Anti-aging and optimization clinics deployed that language during the compounding era, when ipamorelin was available through 503A pharmacies off-label for GH-axis protocols. Recovery claims, lean tissue preservation, and improved sleep quality dominated the conversation. The Grove case reveals that elite sport absorbed those claims as well — that the compound was worth the WADA risk because the recovery signal was real enough to act on. What the stack-culture framing consistently leaves out: that controlled human trial data for those specific recovery and optimization claims does not exist, that the compounding window closed in September 2023 when the FDA listed ipamorelin as a Category 2 substance, and that the company that ran the only serious human trial program walked away after the results came back.
What the data says
one Phase 2 trial, a failed endpoint, and the reason Novo Nordisk discontinued the program
Ipamorelin was developed by Novo Nordisk as a potential treatment for postoperative ileus — the slowed gastrointestinal motility that follows abdominal surgery. The drug's effect on the GH axis was documented pharmacologically, but the intended therapeutic target was the gut, not the growth hormone system. The pivotal Phase 2 randomized controlled trial in postoperative ileus patients did not meet its primary endpoint. Novo Nordisk discontinued the program. The compound never reached Phase 3, never accumulated a regulatory dossier for any approved indication, and was never approved for human use in any jurisdiction. [ClinicalTrials.gov's ipamorelin records](https://clinicaltrials.gov/search?term=Ipamorelin) document the limited scope of what was studied: a pharmacokinetics characterization and the discontinued ileus program. There are no completed controlled trials for GH-axis optimization, body composition, recovery, or anti-aging in any population. In September 2023, the [FDA placed ipamorelin on the Category 2 bulk drug substances list](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) — substances the agency determined present significant safety risks when used in compounding and should not be included in compounded preparations for human administration. That action predated Grove's July 28 out-of-competition test by nearly three years. The compound was already banned in sport, already removed from the legal compounding market, and already carrying a failed trial record when it appeared in a doping sample at the Glasgow Commonwealth Games.
Early human — PeptideFactCheck stance
the tier holds — a doping prohibition and a clinical endorsement are not the same thing
Ipamorelin holds PeptideFactCheck's Early human evidence tier. The classification reflects what the record contains: pharmacokinetics data in humans, a Phase 2 trial in a disease context the compound was designed to treat, and a failed primary endpoint in that trial. That is preliminary human work — enough to place it above pure preclinical status, not enough to support the GH-optimization or recovery claims that drive current interest. The Early human tone: interesting enough to watch, too early for broad certainty. The Grove case, still unresolved as of October 2026, does not change the tier. WADA's prohibition is a competitive-integrity judgment: the compound is pharmacologically active enough to potentially confer a performance advantage, so it is banned at all times regardless of what the controlled-trial record shows. A compound does not need to be proven effective to earn a WADA ban — the precautionary logic runs in the opposite direction from clinical evidence. The FDA's Category 2 classification is the regulatory record for compounding: safety concerns unresolved, no approved human use, compounding barred since September 2023. Neither the doping prohibition nor the compounding restriction is a clinical endorsement. What the tier says — and what this case does not change — is that ipamorelin remains a pharmacologically interesting GH secretagogue with a thin, failed clinical record and no approved human indication. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.